{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,23]],"date-time":"2026-10-23T21:45:49Z","timestamp":1792791949736,"version":"4.5.0"},"reference-count":150,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2019,1,1]],"date-time":"2019-01-01T00:00:00Z","timestamp":1546300800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2019,1,1]],"date-time":"2019-01-01T00:00:00Z","timestamp":1546300800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2019,1,1]],"date-time":"2019-01-01T00:00:00Z","timestamp":1546300800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2019,1,1]],"date-time":"2019-01-01T00:00:00Z","timestamp":1546300800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2019,1,1]],"date-time":"2019-01-01T00:00:00Z","timestamp":1546300800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2019,1,1]],"date-time":"2019-01-01T00:00:00Z","timestamp":1546300800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2019,1,1]],"date-time":"2019-01-01T00:00:00Z","timestamp":1546300800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"funder":[{"DOI":"10.13039\/100006662","name":"National Institute on Handicapped Research","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100006662","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100000265","name":"Medical Research Council","doi-asserted-by":"publisher","award":["MR\/L006340\/1"],"award-info":[{"award-number":["MR\/L006340\/1"]}],"id":[{"id":"10.13039\/501100000265","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100000265","name":"Medical Research Council","doi-asserted-by":"publisher","award":["MR\/S001190\/1"],"award-info":[{"award-number":["MR\/S001190\/1"]}],"id":[{"id":"10.13039\/501100000265","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Advances in Biological Regulation"],"published-print":{"date-parts":[[2019,1]]},"DOI":"10.1016\/j.jbior.2018.11.007","type":"journal-article","created":{"date-parts":[[2018,11,22]],"date-time":"2018-11-22T05:56:17Z","timestamp":1542866177000},"page":"55-68","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":44,"special_numbering":"C","title":["Heterogeneity in myeloproliferative neoplasms: Causes and consequences"],"prefix":"10.1016","volume":"71","author":[{"given":"Jennifer","family":"O'Sullivan","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Adam J.","family":"Mead","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"22","key":"10.1016\/j.jbior.2018.11.007_bib1","doi-asserted-by":"crossref","first-page":"2894","DOI":"10.1182\/blood.V114.22.2894.2894","article-title":"<em>TET2<\/em> and <em>ASXL1<\/em> mutations in leukemic transformation of chronic myeloproliferative neoplasms","volume":"114","author":"Abdel-Wahab","year":"2009","journal-title":"Blood"},{"issue":"7","key":"10.1016\/j.jbior.2018.11.007_bib2","doi-asserted-by":"crossref","first-page":"893","DOI":"10.3324\/haematol.2014.118299","article-title":"Analysis of phenotype and outcome in essential thrombocythemia with <em>CALR<\/em> or <em>JAK2<\/em> mutations","volume":"100","author":"Al Assaf","year":"2015","journal-title":"Haematologica"},{"key":"10.1016\/j.jbior.2018.11.007_bib3","doi-asserted-by":"crossref","first-page":"1218","DOI":"10.1038\/sj.leu.2404693","article-title":"Essential thrombocythemia in young individuals: frequency and risk factors for vascular events and evolution to myelofibrosis in 126 patients","volume":"21","author":"Alvarez-Larr\u00e1n","year":"2007","journal-title":"Leukemia"},{"issue":"12","key":"10.1016\/j.jbior.2018.11.007_bib4","doi-asserted-by":"crossref","first-page":"2037","DOI":"10.1007\/s00277-014-2152-7","article-title":"Busulfan in patients with polycythemia vera or essential thrombocythemia refractory or intolerant to hydroxyurea","volume":"93","author":"Alvarez-Larran","year":"2014","journal-title":"Ann. Hematol."},{"issue":"2","key":"10.1016\/j.jbior.2018.11.007_bib5","doi-asserted-by":"crossref","first-page":"175","DOI":"10.1002\/ajh.22212","article-title":"Environmental, lifestyle, and familial\/ethnic factors associated with myeloproliferative neoplasms","volume":"87","author":"Anderson","year":"2012","journal-title":"Am. J. Hematol."},{"key":"10.1016\/j.jbior.2018.11.007_bib6","doi-asserted-by":"crossref","first-page":"e463","DOI":"10.1038\/bcj.2016.75","article-title":"Molecular characterisation of triple negative essential thrombocythaemia patients by platelet analysis and targeted sequencing","volume":"6","author":"Angona","year":"2016","journal-title":"Blood Canc. J."},{"key":"10.1016\/j.jbior.2018.11.007_bib7","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1016\/j.leukres.2016.06.009","article-title":"Characterization of CD34+ hematopoietic progenitor cells in JAK2V617F and CALR-mutated myeloproliferative neoplasms","volume":"48","author":"Angona","year":"2016","journal-title":"Leuk. Res."},{"issue":"20","key":"10.1016\/j.jbior.2018.11.007_bib8","doi-asserted-by":"crossref","first-page":"2391","DOI":"10.1182\/blood-2016-03-643544","article-title":"The 2016 revision to the World Health Organization classification of myeloid neoplasms and acute leukemia","volume":"127","author":"Arber","year":"2016","journal-title":"Blood"},{"issue":"7512","key":"10.1016\/j.jbior.2018.11.007_bib9","doi-asserted-by":"crossref","first-page":"78","DOI":"10.1038\/nature13383","article-title":"Neuropathy of haematopoietic stem cell niche is essential for myeloproliferative neoplasms","volume":"512","author":"Arranz","year":"2014","journal-title":"Nature"},{"issue":"1","key":"10.1016\/j.jbior.2018.11.007_bib10","first-page":"52","article-title":"Masked polycythemia Vera (mPV)","volume":"89","author":"Barbui","year":"2014","journal-title":"Results of an international study"},{"key":"10.1016\/j.jbior.2018.11.007_bib11","doi-asserted-by":"crossref","first-page":"992","DOI":"10.1038\/leu.2014.328","article-title":"The rate of transformation from JAK2-mutated ET to PV is influenced by an accurate WHO-defined clinico-morphological diagnosis","volume":"29","author":"Barbui","year":"2014","journal-title":"Leukemia"},{"issue":"5","key":"10.1016\/j.jbior.2018.11.007_bib12","doi-asserted-by":"crossref","first-page":"1057","DOI":"10.1038\/s41375-018-0077-1","article-title":"Philadelphia chromosome-negative classical myeloproliferative neoplasms: revised management recommendations from European LeukemiaNet","volume":"32","author":"Barbui","year":"2018","journal-title":"Leukemia"},{"issue":"9464","key":"10.1016\/j.jbior.2018.11.007_bib13","doi-asserted-by":"crossref","first-page":"1054","DOI":"10.1016\/S0140-6736(05)71142-9","article-title":"Acquired mutation of the tyrosine kinase JAK2 in human myeloproliferative disorders","volume":"365","author":"Baxter","year":"2005","journal-title":"Lancet"},{"issue":"12","key":"10.1016\/j.jbior.2018.11.007_bib14","doi-asserted-by":"crossref","first-page":"2153","DOI":"10.3324\/haematol.2010.029306","article-title":"Molecular mechanisms associated with leukemic transformation of MPL-mutant myeloproliferative neoplasms","volume":"95","author":"Beer","year":"2010","journal-title":"Haematologica"},{"issue":"1","key":"10.1016\/j.jbior.2018.11.007_bib15","doi-asserted-by":"crossref","first-page":"51","DOI":"10.3324\/haematol.2017.174672","article-title":"Treatment of essential thrombocythemia in Europe: a prospective long-term observational study of 3649 high-risk patients in the Evaluation of Anagrelide Efficacy and Long-term Safety study","volume":"103","author":"Birgeg\u00e5rd","year":"2018","journal-title":"Haematologica"},{"issue":"23","key":"10.1016\/j.jbior.2018.11.007_bib16","doi-asserted-by":"crossref","first-page":"3542","DOI":"10.1182\/blood-2014-12-618090","article-title":"TGF-beta signaling in the control of hematopoietic stem cells","volume":"125","author":"Blank","year":"2015","journal-title":"Blood"},{"issue":"1","key":"10.1016\/j.jbior.2018.11.007_bib17","doi-asserted-by":"crossref","first-page":"249","DOI":"10.1038\/leu.2014.270","article-title":"Differential association of calreticulin type 1 and type 2 mutations with myelofibrosis and essential thrombocytemia: relevance for disease evolution","volume":"29","author":"Cabagnols","year":"2015","journal-title":"Leukemia"},{"issue":"3","key":"10.1016\/j.jbior.2018.11.007_bib18","doi-asserted-by":"crossref","first-page":"333","DOI":"10.1182\/blood-2015-07-661983","article-title":"Presence of atypical thrombopoietin receptor (MPL) mutations in triple-negative essential thrombocythemia patients","volume":"127","author":"Cabagnols","year":"2016","journal-title":"Blood"},{"issue":"22","key":"10.1016\/j.jbior.2018.11.007_bib19","doi-asserted-by":"crossref","first-page":"2443","DOI":"10.1182\/blood-2015-07-533588","article-title":"The hematopoietic stem cell niche in homeostasis and disease","volume":"126","author":"Calvi","year":"2015","journal-title":"Blood"},{"issue":"11","key":"10.1016\/j.jbior.2018.11.007_bib20","doi-asserted-by":"crossref","first-page":"e366","DOI":"10.1038\/bcj.2015.95","article-title":"Blast transformation and fibrotic progression in polycythemia vera and essential thrombocythemia: a literature review of incidence and risk factors","volume":"5","author":"Cerquozzi","year":"2015","journal-title":"Blood Canc. J."},{"issue":"10","key":"10.1016\/j.jbior.2018.11.007_bib21","doi-asserted-by":"crossref","first-page":"1325","DOI":"10.1182\/blood-2015-11-681932","article-title":"Thrombopoietin receptor activation by myeloproliferative neoplasm associated calreticulin mutants","volume":"127","author":"Chachoua","year":"2016","journal-title":"Blood"},{"issue":"1","key":"10.1016\/j.jbior.2018.11.007_bib22","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1038\/ng.1009","article-title":"Dnmt3a is essential for hematopoietic stem cell differentiation","volume":"44","author":"Challen","year":"2011","journal-title":"Nat. Genet."},{"issue":"5","key":"10.1016\/j.jbior.2018.11.007_bib23","doi-asserted-by":"crossref","first-page":"524","DOI":"10.1016\/j.ccr.2010.10.013","article-title":"Distinct clinical phenotypes associated with JAK2V617F reflect differential STAT1 signaling","volume":"18","author":"Chen","year":"2010","journal-title":"Cancer Cell"},{"issue":"2","key":"10.1016\/j.jbior.2018.11.007_bib24","doi-asserted-by":"crossref","first-page":"327","DOI":"10.1182\/blood-2014-04-567024","article-title":"Distinct effects of concomitant Jak2V617F expression and Tet2 loss in mice promote disease progression in myeloproliferative neoplasms","volume":"125","author":"Chen","year":"2015","journal-title":"Blood"},{"issue":"21","key":"10.1016\/j.jbior.2018.11.007_bib25","doi-asserted-by":"crossref","first-page":"4074","DOI":"10.1182\/blood.V122.21.4074.4074","article-title":"Cytokine profile changes in 309 myelofibrosis patients: comparison of JAK1\/JAK2 inhibitor therapy vs. Placebo \u2013 correlative analysis from the comfort-I trial","volume":"122","author":"Cleeland","year":"2013","journal-title":"Blood"},{"issue":"7265","key":"10.1016\/j.jbior.2018.11.007_bib26","doi-asserted-by":"crossref","first-page":"819","DOI":"10.1038\/nature08448","article-title":"JAK2 phosphorylates histone H3Y41 and excludes HP1\u03b1 from chromatin","volume":"461","author":"Dawson","year":"2009","journal-title":"Nature"},{"issue":"5","key":"10.1016\/j.jbior.2018.11.007_bib27","doi-asserted-by":"crossref","first-page":"479","DOI":"10.1182\/blood-2017-06-746412","article-title":"Aging of hematopoietic stem cells","volume":"131","author":"de Haan","year":"2018","journal-title":"Blood"},{"issue":"1","key":"10.1016\/j.jbior.2018.11.007_bib28","doi-asserted-by":"crossref","first-page":"71","DOI":"10.1182\/blood-2006-03-007146","article-title":"Evidence that the JAK2 G1849T (V617F) mutation occurs in a lymphomyeloid progenitor in polycythemia vera and idiopathic myelofibrosis","volume":"109","author":"Delhommeau","year":"2007","journal-title":"Blood"},{"issue":"22","key":"10.1016\/j.jbior.2018.11.007_bib29","doi-asserted-by":"crossref","first-page":"2289","DOI":"10.1056\/NEJMoa0810069","article-title":"Mutation in TET2 in myeloid cancers","volume":"360","author":"Delhommeau","year":"2009","journal-title":"N. Engl. J. Med."},{"issue":"14","key":"10.1016\/j.jbior.2018.11.007_bib30","doi-asserted-by":"crossref","first-page":"2254","DOI":"10.1182\/blood-2014-08-595561","article-title":"Programmable 3D silk bone marrow niche for platelet generation ex vivo and modeling of megakaryopoiesis pathologies","volume":"125","author":"Di Buduo","year":"2015","journal-title":"Blood"},{"issue":"17","key":"10.1016\/j.jbior.2018.11.007_bib31","doi-asserted-by":"crossref","first-page":"2605","DOI":"10.1182\/blood-2014-12-570200","article-title":"Hematopoietic stem cells: concepts, definitions, and the new reality","volume":"125","author":"Eaves","year":"2015","journal-title":"Blood"},{"issue":"4","key":"10.1016\/j.jbior.2018.11.007_bib32","doi-asserted-by":"crossref","first-page":"368","DOI":"10.1158\/2159-8290.CD-15-1434","article-title":"Mutant calreticulin requires both its mutant C-terminus and the thrombopoietin receptor for oncogenic transformation","volume":"6","author":"Elf","year":"2016","journal-title":"Cancer Discov."},{"issue":"1","key":"10.1016\/j.jbior.2018.11.007_bib33","doi-asserted-by":"crossref","first-page":"85","DOI":"10.3324\/haematol.2016.149559","article-title":"Associations between gender, disease features and symptom burden in patients with myeloproliferative neoplasms: an analysis by the MPN QOL International Working Group","volume":"102","author":"Geyer","year":"2017","journal-title":"Haematologica"},{"issue":"21","key":"10.1016\/j.jbior.2018.11.007_bib34","first-page":"267","article-title":"Germline <em>RBBP6<\/em> mutations in myeloproliferative neoplasms","volume":"122","author":"Giambruno","year":"2013","journal-title":"Blood"},{"issue":"11","key":"10.1016\/j.jbior.2018.11.007_bib35","doi-asserted-by":"crossref","first-page":"661","DOI":"10.1182\/blood.V112.11.661.661","article-title":"Final results of the ANAHYDRET-study: non-inferiority of anagrelide compared to hydroxyurea in newly diagnosed WHO-essential thrombocythemia patients","volume":"112","author":"Gisslinger","year":"2008","journal-title":"Blood"},{"issue":"22","key":"10.1016\/j.jbior.2018.11.007_bib36","doi-asserted-by":"crossref","first-page":"475","DOI":"10.1182\/blood.V128.22.475.475","article-title":"Final results from PROUD-PV a randomized controlled phase 3 trial comparing ropeginterferon alfa-2b to hydroxyurea in polycythemia vera patients","volume":"128","author":"Gisslinger","year":"2016","journal-title":"Blood"},{"issue":"13","key":"10.1016\/j.jbior.2018.11.007_bib37","doi-asserted-by":"crossref","first-page":"2704","DOI":"10.1182\/blood-2012-05-431791","article-title":"JAK2V617F homozygosity arises commonly and recurrently in PV and ET, but PV is characterized by expansion of a dominant homozygous subclone","volume":"120","author":"Godfrey","year":"2012","journal-title":"Blood"},{"issue":"5","key":"10.1016\/j.jbior.2018.11.007_bib38","doi-asserted-by":"crossref","first-page":"718","DOI":"10.3324\/haematol.2012.079129","article-title":"Clonal analyses reveal associations of JAK2V617F homozygosity with hematologic features, age and gender in polycythemia vera and essential thrombocythemia","volume":"98","author":"Godfrey","year":"2013","journal-title":"Haematologica"},{"issue":"3","key":"10.1016\/j.jbior.2018.11.007_bib39","doi-asserted-by":"crossref","first-page":"665","DOI":"10.1096\/fj.09-145482","article-title":"Calreticulin: non-endoplasmic reticulum functions in physiology and disease","volume":"24","author":"Gold","year":"2010","journal-title":"Faseb. J."},{"issue":"15","key":"10.1016\/j.jbior.2018.11.007_bib40","doi-asserted-by":"crossref","first-page":"1416","DOI":"10.1056\/NEJMoa1716614","article-title":"Classification and personalized prognosis in myeloproliferative neoplasms","volume":"379","author":"Grinfeld","year":"2018","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.jbior.2018.11.007_bib41","doi-asserted-by":"crossref","first-page":"11075","DOI":"10.1038\/ncomms11075","article-title":"Single-cell RNA sequencing reveals molecular and functional platelet bias of aged haematopoietic stem cells","volume":"7","author":"Grover","year":"2016","journal-title":"Nat. Commun."},{"issue":"19","key":"10.1016\/j.jbior.2018.11.007_bib42","doi-asserted-by":"crossref","first-page":"5227","DOI":"10.1182\/blood-2011-06-363424","article-title":"EZH2 mutational status predicts poor survival in myelofibrosis","volume":"118","author":"Guglielmelli","year":"2011","journal-title":"Blood"},{"issue":"9","key":"10.1016\/j.jbior.2018.11.007_bib43","doi-asserted-by":"crossref","first-page":"1804","DOI":"10.1038\/leu.2014.76","article-title":"The number of prognostically detrimental mutations and prognosis in primary myelofibrosis: an international study of 797 patients","volume":"28","author":"Guglielmelli","year":"2014","journal-title":"Leukemia"},{"issue":"10","key":"10.1016\/j.jbior.2018.11.007_bib44","doi-asserted-by":"crossref","first-page":"e487","DOI":"10.1038\/bcj.2016.98","article-title":"MPL mutations and palpable splenomegaly are independent risk factors for fibrotic progression in essential thrombocythemia","volume":"6","author":"Haider","year":"2016","journal-title":"Blood Canc. J."},{"issue":"1","key":"10.1016\/j.jbior.2018.11.007_bib45","first-page":"33","volume":"353","author":"Harrison","year":"2005","journal-title":"Hydroxyurea Compared with Anagrelide in High-Risk Essential Thrombocythemia"},{"issue":"9","key":"10.1016\/j.jbior.2018.11.007_bib46","doi-asserted-by":"crossref","first-page":"787","DOI":"10.1056\/NEJMoa1110556","article-title":"JAK inhibition with ruxolitinib versus best available therapy for myelofibrosis","volume":"366","author":"Harrison","year":"2012","journal-title":"N. Engl. J. Med."},{"issue":"3","key":"10.1016\/j.jbior.2018.11.007_bib47","doi-asserted-by":"crossref","first-page":"421","DOI":"10.1111\/bjh.12986","article-title":"Modification of British committee for standards in Haematology diagnostic criteria for essential thrombocythaemia","volume":"167","author":"Harrison","year":"2014","journal-title":"Br. J. Haematol."},{"issue":"8","key":"10.1016\/j.jbior.2018.11.007_bib48","doi-asserted-by":"crossref","first-page":"1701","DOI":"10.1038\/leu.2016.148","article-title":"Long-term findings from COMFORT-II, a phase 3 study of ruxolitinib vs best available therapy for myelofibrosis","volume":"30","author":"Harrison","year":"2016","journal-title":"Leukemia"},{"issue":"7","key":"10.1016\/j.jbior.2018.11.007_bib49","doi-asserted-by":"crossref","first-page":"1660","DOI":"10.1038\/leu.2017.119","article-title":"Equivalence of BCSH and WHO diagnostic criteria for ET","volume":"31","author":"Harrison","year":"2017","journal-title":"Leukemia"},{"issue":"8","key":"10.1016\/j.jbior.2018.11.007_bib50","doi-asserted-by":"crossref","first-page":"1121","DOI":"10.1182\/blood-2015-06-652941","article-title":"Germ line variants predispose to both <em>JAK2<\/em> V617F clonal hematopoiesis and myeloproliferative neoplasms","volume":"128","author":"Hinds","year":"2016","journal-title":"Blood"},{"issue":"26","key":"10.1016\/j.jbior.2018.11.007_bib51","doi-asserted-by":"crossref","first-page":"2488","DOI":"10.1056\/NEJMoa1408617","article-title":"Age-related clonal hematopoiesis associated with adverse outcomes","volume":"371","author":"Jaiswal","year":"2014","journal-title":"N. Engl. J. Med."},{"issue":"6","key":"10.1016\/j.jbior.2018.11.007_bib52","doi-asserted-by":"crossref","first-page":"2429","DOI":"10.1182\/blood-2008-02-137877","article-title":"The hematopoietic stem cell compartment of JAK2V617F-positive myeloproliferative disorders is a reflection of disease heterogeneity","volume":"112","author":"James","year":"2008","journal-title":"Blood"},{"issue":"16","key":"10.1016\/j.jbior.2018.11.007_bib53","doi-asserted-by":"crossref","first-page":"6224","DOI":"10.1073\/pnas.0601462103","article-title":"The JAK2 V617F mutation occurs in hematopoietic stem cells in polycythemia vera and predisposes toward erythroid differentiation","volume":"103","author":"Jamieson","year":"2006","journal-title":"Proc. Natl. Acad. Sci. U. S. A."},{"issue":"Suppl. 1","key":"10.1016\/j.jbior.2018.11.007_bib54","first-page":"4199","article-title":"Cigarette smoking, complete blood count, and myeloproliferative neoplasms \u2014 a meta-analysis","volume":"130","author":"Jayasuriya","year":"2017","journal-title":"Blood"},{"issue":"4","key":"10.1016\/j.jbior.2018.11.007_bib55","doi-asserted-by":"crossref","first-page":"446","DOI":"10.1038\/ng.334","article-title":"JAK2 haplotype is a major risk factor for the development of myeloproliferative neoplasms","volume":"41","author":"Jones","year":"2009","journal-title":"Nat. Genet."},{"issue":"22","key":"10.1016\/j.jbior.2018.11.007_bib56","doi-asserted-by":"crossref","first-page":"4517","DOI":"10.1182\/blood-2009-08-236448","article-title":"The JAK2 46\/1 haplotype predisposes to MPL-mutated myeloproliferative neoplasms","volume":"115","author":"Jones","year":"2010","journal-title":"Blood"},{"issue":"5","key":"10.1016\/j.jbior.2018.11.007_bib57","doi-asserted-by":"crossref","first-page":"1003","DOI":"10.1084\/jem.20120521","article-title":"MPN patients harbor recurrent truncating mutations in transcription factor NF-E2","volume":"210","author":"Jutzi","year":"2013","journal-title":"J. Exp. Med."},{"issue":"19","key":"10.1016\/j.jbior.2018.11.007_bib58","doi-asserted-by":"crossref","first-page":"2996","DOI":"10.1182\/blood-2014-04-570572","article-title":"JAK2V617F+ myeloproliferative neoplasm clones evoke paracrine DNA damage to adjacent normal cells through secretion of lipocalin-2","volume":"124","author":"Kagoya","year":"2014","journal-title":"Blood"},{"issue":"2","key":"10.1016\/j.jbior.2018.11.007_bib59","doi-asserted-by":"crossref","first-page":"304","DOI":"10.1182\/blood-2014-04-555508","article-title":"Loss of TET2 has dual roles in murine myeloproliferative neoplasms: disease sustainer and disease accelerator","volume":"125","author":"Kameda","year":"2015","journal-title":"Blood"},{"issue":"6","key":"10.1016\/j.jbior.2018.11.007_bib60","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pbio.1001576","article-title":"Self-renewal of single mouse hematopoietic stem cells is reduced by JAK2V617F without compromising progenitor cell expansion","volume":"11","author":"Kent","year":"2013","journal-title":"PLoS Biol."},{"issue":"4 Pt 2","key":"10.1016\/j.jbior.2018.11.007_bib61","doi-asserted-by":"crossref","first-page":"417","DOI":"10.1055\/s-2006-942762","article-title":"Long-term incidence of hematological evolution in three French prospective studies of hydroxyurea and pipobroman in polycythemia vera and essential thrombocythemia","volume":"32","author":"Kiladjian","year":"2006","journal-title":"Semin. Thromb. Hemost."},{"issue":"8","key":"10.1016\/j.jbior.2018.11.007_bib62","doi-asserted-by":"crossref","first-page":"3065","DOI":"10.1182\/blood-2008-03-143537","article-title":"Pegylated interferon-alfa-2a induces complete hematologic and molecular responses with low toxicity in polycythemia vera","volume":"112","author":"Kiladjian","year":"2008","journal-title":"Blood"},{"issue":"5","key":"10.1016\/j.jbior.2018.11.007_bib63","doi-asserted-by":"crossref","first-page":"617","DOI":"10.1016\/j.ccell.2015.04.006","article-title":"SRSF2 mutations contribute to myelodysplasia by mutant-specific effects on exon recognition","volume":"27","author":"Kim","year":"2015","journal-title":"Cancer Cell"},{"issue":"10","key":"10.1016\/j.jbior.2018.11.007_bib64","doi-asserted-by":"crossref","first-page":"912","DOI":"10.1016\/j.exphem.2015.05.013","article-title":"Comparative long-term effects of interferon \u03b1 and hydroxyurea on human hematopoietic progenitor cells","volume":"43","author":"King","year":"2015","journal-title":"Exp. Hematol."},{"issue":"25","key":"10.1016\/j.jbior.2018.11.007_bib65","doi-asserted-by":"crossref","first-page":"2379","DOI":"10.1056\/NEJMoa1311347","article-title":"Somatic mutations of calreticulin in myeloproliferative neoplasms","volume":"369","author":"Klampfl","year":"2013","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.jbior.2018.11.007_bib66","doi-asserted-by":"crossref","first-page":"934","DOI":"10.1038\/leu.2016.280","article-title":"A novel signalling screen demonstrates that CALR mutations activate essential MAPK signalling and facilitate megakaryocyte differentiation","volume":"31","author":"Kollmann","year":"2016","journal-title":"Leukemia"},{"issue":"2","key":"10.1016\/j.jbior.2018.11.007_bib67","first-page":"119","article-title":"The involvement of Galectins in the modulation of the JAK\/STAT pathway in myeloproliferative neoplasia","volume":"2","author":"Koopmans","year":"2012","journal-title":"American journal of blood research"},{"key":"10.1016\/j.jbior.2018.11.007_bib68","series-title":"Niche Heterogeneity Impacts Evolution of Myeloproliferative Neoplasms Driven by the Same Oncogenic Pathway","first-page":"USA2018","author":"Korn","year":"2018"},{"issue":"17","key":"10.1016\/j.jbior.2018.11.007_bib69","doi-asserted-by":"crossref","first-page":"1779","DOI":"10.1056\/NEJMoa051113","article-title":"A gain-of-function mutation of JAK2 in myeloproliferative disorders","volume":"352","author":"Kralovics","year":"2005","journal-title":"N. Engl. J. Med."},{"issue":"2","key":"10.1016\/j.jbior.2018.11.007_bib70","doi-asserted-by":"crossref","first-page":"450","DOI":"10.1038\/leu.2017.230","article-title":"Low-burden TP53 mutations in chronic phase of myeloproliferative neoplasms: association with age, hydroxyurea administration, disease type and JAK2 mutational status","volume":"32","author":"Kubesova","year":"2018","journal-title":"Leukemia"},{"issue":"6","key":"10.1016\/j.jbior.2018.11.007_bib71","doi-asserted-by":"crossref","first-page":"2199","DOI":"10.1182\/blood-2008-03-143602","article-title":"Increased risks of polycythemia vera, essential thrombocythemia, and myelofibrosis among 24\u2009577 first-degree relatives of 11\u2009039 patients with myeloproliferative neoplasms in Sweden","volume":"112","author":"Landgren","year":"2008","journal-title":"Blood"},{"issue":"20","key":"10.1016\/j.jbior.2018.11.007_bib72","doi-asserted-by":"crossref","first-page":"4168","DOI":"10.1182\/blood-2012-05-429696","article-title":"<em>SRSF2<\/em> mutations in primary myelofibrosis: significant clustering with <em>IDH<\/em> mutations and independent association with inferior overall and leukemia-free survival","volume":"120","author":"Lasho","year":"2012","journal-title":"Blood"},{"issue":"4","key":"10.1016\/j.jbior.2018.11.007_bib73","doi-asserted-by":"crossref","first-page":"370","DOI":"10.1182\/bloodadvances.2018015875","article-title":"Targeted next-generation sequencing in blast phase myeloproliferative neoplasms","volume":"2","author":"Lasho","year":"2018","journal-title":"Blood advances"},{"issue":"20","key":"10.1016\/j.jbior.2018.11.007_bib74","doi-asserted-by":"crossref","first-page":"3139","DOI":"10.1182\/blood-2013-06-510222","article-title":"<em>JAK2V617F<em> homozygosity drives a phenotypic switch in myeloproliferative neoplasms, but is insufficient to sustain disease","volume":"123","author":"Li","year":"2014","journal-title":"Blood"},{"issue":"22","key":"10.1016\/j.jbior.2018.11.007_bib75","doi-asserted-by":"crossref","first-page":"1942","DOI":"10.1182\/blood.V128.22.1942.1942","article-title":"Non-driver mutations profile identified by a 206-gene NGS panel in patients with primary myelofibrosis and post-polycythaemic\/essential thromocythaemia myelofibrosis in a single center from China","volume":"128","author":"Li","year":"2016","journal-title":"Blood"},{"issue":"6","key":"10.1016\/j.jbior.2018.11.007_bib76","doi-asserted-by":"crossref","first-page":"649","DOI":"10.1182\/blood-2017-09-806356","article-title":"Mutant calreticulin knockin mice develop thrombocytosis and myelofibrosis without a stem cell self-renewal advantage","volume":"131","author":"Li","year":"2018","journal-title":"Blood"},{"issue":"7","key":"10.1016\/j.jbior.2018.11.007_bib77","doi-asserted-by":"crossref","first-page":"1160","DOI":"10.3324\/haematol.2017.185736","article-title":"JAK2V617F-bearing vascular niche enhances malignant hematopoietic regeneration following radiation injury","volume":"103","author":"Lin","year":"2018","journal-title":"Haematologica"},{"issue":"2","key":"10.1016\/j.jbior.2018.11.007_bib78","doi-asserted-by":"crossref","first-page":"283","DOI":"10.1016\/j.ccr.2010.12.020","article-title":"JAK2V617F-mediated phosphorylation of PRMT5 downregulates its methyltransferase activity and promotes myeloproliferation","volume":"19","author":"Liu","year":"2011","journal-title":"Cancer Cell"},{"issue":"14","key":"10.1016\/j.jbior.2018.11.007_bib79","doi-asserted-by":"crossref","first-page":"2220","DOI":"10.1182\/blood-2013-11-537167","article-title":"Clonal evolution and clinical correlates of somatic mutations in myeloproliferative neoplasms","volume":"123","author":"Lundberg","year":"2014","journal-title":"Blood"},{"issue":"11","key":"10.1016\/j.jbior.2018.11.007_bib80","doi-asserted-by":"crossref","first-page":"2213","DOI":"10.1084\/jem.20131371","article-title":"Myeloproliferative neoplasms can be initiated from a single hematopoietic stem cell expressing JAK2-V617F","volume":"211","author":"Lundberg","year":"2014","journal-title":"J. Exp. Med."},{"issue":"2","key":"10.1016\/j.jbior.2018.11.007_bib81","doi-asserted-by":"crossref","first-page":"233","DOI":"10.1182\/blood-2015-03-633537","article-title":"SF3B1 mutation identifies a distinct subset of myelodysplastic syndrome with ring sideroblasts","volume":"126","author":"Malcovati","year":"2015","journal-title":"Blood"},{"issue":"10","key":"10.1016\/j.jbior.2018.11.007_bib82","doi-asserted-by":"crossref","first-page":"1317","DOI":"10.1182\/blood-2015-11-679571","article-title":"Calreticulin mutants in mice induce an MPL-dependent thrombocytosis with frequent progression to myelofibrosis","volume":"127","author":"Marty","year":"2016","journal-title":"Blood"},{"issue":"8","key":"10.1016\/j.jbior.2018.11.007_bib83","doi-asserted-by":"crossref","first-page":"1931","DOI":"10.1182\/blood.V79.8.1931.1931","article-title":"Analysis of the mechanism of anagrelide-induced thrombocytopenia in humans","volume":"79","author":"Mazur","year":"1992","journal-title":"Blood"},{"issue":"12","key":"10.1016\/j.jbior.2018.11.007_bib84","doi-asserted-by":"crossref","first-page":"1607","DOI":"10.1182\/blood-2016-10-696005","article-title":"Myeloproliferative neoplasm stem cells","volume":"129","author":"Mead","year":"2017","journal-title":"Blood"},{"issue":"21","key":"10.1016\/j.jbior.2018.11.007_bib85","doi-asserted-by":"crossref","first-page":"1738","DOI":"10.1182\/blood.V118.21.1738.1738","article-title":"Germline activating JAK2 V617I mutation in a family with hereditary thrombocytosis","volume":"118","author":"Mead","year":"2011","journal-title":"Blood"},{"issue":"10","key":"10.1016\/j.jbior.2018.11.007_bib86","doi-asserted-by":"crossref","first-page":"967","DOI":"10.1056\/NEJMc1200349","article-title":"Germline JAK2 mutation in a family with hereditary thrombocytosis","volume":"366","author":"Mead","year":"2012","journal-title":"N. Engl. J. Med."},{"issue":"3","key":"10.1016\/j.jbior.2018.11.007_bib87","doi-asserted-by":"crossref","first-page":"325","DOI":"10.1182\/blood-2015-07-661835","article-title":"Whole-exome sequencing identifies novel MPL and JAK2 mutations in triple-negative myeloproliferative neoplasms","volume":"127","author":"Milosevic Feenstra","year":"2016","journal-title":"Blood"},{"issue":"1","key":"10.1016\/j.jbior.2018.11.007_bib88","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1016\/j.ccr.2011.06.001","article-title":"Tet2 loss leads to increased hematopoietic stem cell self-renewal and myeloid transformation","volume":"20","author":"Moran-Crusio","year":"2011","journal-title":"Cancer Cell"},{"issue":"4","key":"10.1016\/j.jbior.2018.11.007_bib89","doi-asserted-by":"crossref","first-page":"289","DOI":"10.1111\/ejh.12256","article-title":"Epidemiology of myelofibrosis, essential thrombocythemia, and polycythemia vera in the European Union","volume":"92","author":"Moulard","year":"2014","journal-title":"Eur. J. Haematol."},{"issue":"6","key":"10.1016\/j.jbior.2018.11.007_bib90","doi-asserted-by":"crossref","first-page":"584","DOI":"10.1016\/j.ccr.2010.05.015","article-title":"Physiological Jak2V617F expression causes a lethal myeloproliferative neoplasm with differential effects on hematopoietic stem and progenitor cells","volume":"17","author":"Mullally","year":"2010","journal-title":"Cancer Cell"},{"issue":"18","key":"10.1016\/j.jbior.2018.11.007_bib91","doi-asserted-by":"crossref","first-page":"3692","DOI":"10.1182\/blood-2012-05-432989","article-title":"Depletion of Jak2V617F myeloproliferative neoplasm-propagating stem cells by interferon-alpha in a murine model of polycythemia vera","volume":"121","author":"Mullally","year":"2013","journal-title":"Blood"},{"issue":"25","key":"10.1016\/j.jbior.2018.11.007_bib92","doi-asserted-by":"crossref","first-page":"2391","DOI":"10.1056\/NEJMoa1312542","article-title":"Somatic CALR mutations in myeloproliferative neoplasms with nonmutated JAK2","volume":"369","author":"Nangalia","year":"2013","journal-title":"N. Engl. J. Med."},{"issue":"11","key":"10.1016\/j.jbior.2018.11.007_bib93","doi-asserted-by":"crossref","first-page":"e438","DOI":"10.3324\/haematol.2015.129510","article-title":"DNMT3A mutations occur early or late in patients with myeloproliferative neoplasms and mutation order influences phenotype","volume":"100","author":"Nangalia","year":"2015","journal-title":"Haematologica"},{"issue":"6","key":"10.1016\/j.jbior.2018.11.007_bib94","doi-asserted-by":"crossref","first-page":"988","DOI":"10.1182\/blood-2010-02-270108","article-title":"Novel mutations in the inhibitory adaptor protein LNK drive JAK-STAT signaling in patients with myeloproliferative neoplasms","volume":"116","author":"Oh","year":"2010","journal-title":"Blood"},{"issue":"7","key":"10.1016\/j.jbior.2018.11.007_bib95","doi-asserted-by":"crossref","first-page":"601","DOI":"10.1056\/NEJMoa1412098","article-title":"Effect of mutation order on myeloproliferative neoplasms","volume":"372","author":"Ortmann","year":"2015","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.jbior.2018.11.007_bib96","volume":"vol. 23","author":"O'Sullivan","year":"2018"},{"issue":"10","key":"10.1016\/j.jbior.2018.11.007_bib97","doi-asserted-by":"crossref","first-page":"3472","DOI":"10.1182\/blood-2006-04-018879","article-title":"MPL515 mutations in myeloproliferative and other myeloid disorders: a study of 1182 patients","volume":"108","author":"Pardanani","year":"2006","journal-title":"Blood"},{"issue":"10","key":"10.1016\/j.jbior.2018.11.007_bib98","doi-asserted-by":"crossref","first-page":"2813","DOI":"10.1182\/blood-2010-11-316810","article-title":"Molecular and clinical features of the myeloproliferative neoplasm associated with JAK2 exon 12 mutations","volume":"117","author":"Passamonti","year":"2011","journal-title":"Blood"},{"key":"10.1016\/j.jbior.2018.11.007_bib99","doi-asserted-by":"crossref","first-page":"59","DOI":"10.1016\/j.jbior.2016.08.001","article-title":"Splicing factor gene mutations in the myelodysplastic syndromes: impact on disease phenotype and therapeutic applications","volume":"63","author":"Pellagatti","year":"2017","journal-title":"Advances in biological regulation"},{"key":"10.1016\/j.jbior.2018.11.007_bib100","series-title":"Melphalan Treatment in Patients with Myelofibrosis with Myeloid Metaplasia","first-page":"576","author":"Petti","year":"2002"},{"issue":"2","key":"10.1016\/j.jbior.2018.11.007_bib101","doi-asserted-by":"crossref","first-page":"431","DOI":"10.1038\/leu.2015.277","article-title":"Differential clinical effects of different mutation subtypes in CALR-mutant myeloproliferative neoplasms","volume":"30","author":"Pietra","year":"2016","journal-title":"Leukemia"},{"issue":"7","key":"10.1016\/j.jbior.2018.11.007_bib102","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pmed.0030270","article-title":"MPLW515L is a novel somatic activating mutation in myelofibrosis with myeloid metaplasia","volume":"3","author":"Pikman","year":"2006","journal-title":"PLoS Med."},{"issue":"5","key":"10.1016\/j.jbior.2018.11.007_bib103","doi-asserted-by":"crossref","first-page":"360","DOI":"10.1016\/j.exphem.2014.01.006","article-title":"Cytokine profiles in polycythemia vera and essential thrombocythemia patients: clinical implications","volume":"42","author":"Pourcelot","year":"2014","journal-title":"Exp. Hematol."},{"issue":"8","key":"10.1016\/j.jbior.2018.11.007_bib104","doi-asserted-by":"crossref","first-page":"1563","DOI":"10.1084\/jem.20110752","article-title":"Tumor necrosis factor restricts hematopoietic stem cell activity in mice: involvement of two distinct receptors","volume":"208","author":"Pronk","year":"2011","journal-title":"J. Exp. Med."},{"issue":"8","key":"10.1016\/j.jbior.2018.11.007_bib105","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0182470","article-title":"Mesenchymal stromal cells (MSC) from JAK2+ myeloproliferative neoplasms differ from normal MSC and contribute to the maintenance of neoplastic hematopoiesis","volume":"12","author":"Ramos","year":"2017","journal-title":"PLoS One"},{"issue":"22","key":"10.1016\/j.jbior.2018.11.007_bib106","doi-asserted-by":"crossref","first-page":"e123","DOI":"10.1182\/blood-2014-02-554634","article-title":"Integrated genomic analysis illustrates the central role of JAK-STAT pathway activation in myeloproliferative neoplasm pathogenesis","volume":"123","author":"Rampal","year":"2014","journal-title":"Blood"},{"issue":"50","key":"10.1016\/j.jbior.2018.11.007_bib107","doi-asserted-by":"crossref","first-page":"E5401","DOI":"10.1073\/pnas.1407792111","article-title":"Genomic and functional analysis of leukemic transformation of myeloproliferative neoplasms","volume":"111","author":"Rampal","year":"2014","journal-title":"Proc. Natl. Acad. Sci. Unit. States Am."},{"issue":"2","key":"10.1016\/j.jbior.2018.11.007_bib108","doi-asserted-by":"crossref","first-page":"360","DOI":"10.1182\/blood-2012-01-404889","article-title":"Spleen endothelial cells from patients with myelofibrosis harbor the JAK2V617F mutation","volume":"121","author":"Rosti","year":"2013","journal-title":"Blood"},{"issue":"10","key":"10.1016\/j.jbior.2018.11.007_bib109","doi-asserted-by":"crossref","first-page":"1544","DOI":"10.1182\/blood-2013-11-539098","article-title":"JAK2 or CALR mutation status defines subtypes of essential thrombocythemia with substantially different clinical course and outcomes","volume":"123","author":"Rumi","year":"2014","journal-title":"Blood"},{"issue":"7","key":"10.1016\/j.jbior.2018.11.007_bib110","doi-asserted-by":"crossref","first-page":"1062","DOI":"10.1182\/blood-2014-05-578435","article-title":"Clinical effect of driver mutations of JAK2, CALR, or MPL in primary myelofibrosis","volume":"124","author":"Rumi","year":"2014","journal-title":"Blood"},{"issue":"60","key":"10.1016\/j.jbior.2018.11.007_bib111","doi-asserted-by":"crossref","first-page":"101735","DOI":"10.18632\/oncotarget.21594","article-title":"Clinical course and outcome of essential thrombocythemia and prefibrotic myelofibrosis according to the revised WHO 2016 diagnostic criteria","volume":"8","author":"Rumi","year":"2017","journal-title":"Oncotarget"},{"issue":"23","key":"10.1016\/j.jbior.2018.11.007_bib112","doi-asserted-by":"crossref","first-page":"1198","DOI":"10.1182\/blood.V126.23.1198.1198","article-title":"Role of mesenchymal stem cell galectin 3 in the AML tumor microenvironment","volume":"126","author":"Ruvolo","year":"2015","journal-title":"Blood"},{"key":"10.1016\/j.jbior.2018.11.007_bib113","doi-asserted-by":"crossref","first-page":"1131","DOI":"10.1038\/ng.3380","article-title":"Germline duplication of ATG2B and GSKIP predisposes to familial myeloid malignancies","volume":"47","author":"Saliba","year":"2015","journal-title":"Nat. Genet."},{"issue":"7470","key":"10.1016\/j.jbior.2018.11.007_bib114","doi-asserted-by":"crossref","first-page":"232","DOI":"10.1038\/nature12495","article-title":"Platelet-biased stem cells reside at the apex of the haematopoietic stem-cell hierarchy","volume":"502","author":"Sanjuan-Pla","year":"2013","journal-title":"Nature"},{"key":"10.1016\/j.jbior.2018.11.007_bib115","doi-asserted-by":"crossref","first-page":"347270","DOI":"10.1155\/2015\/347270","article-title":"The hematopoietic niche in myeloproliferative neoplasms","volume":"2015","author":"Schmitt-Graeff","year":"2015","journal-title":"Mediat. Inflamm."},{"issue":"5","key":"10.1016\/j.jbior.2018.11.007_bib116","doi-asserted-by":"crossref","first-page":"459","DOI":"10.1056\/NEJMoa065202","article-title":"JAK2 exon 12 mutations in polycythemia vera and idiopathic erythrocytosis","volume":"356","author":"Scott","year":"2007","journal-title":"N. Engl. J. Med."},{"issue":"5","key":"10.1016\/j.jbior.2018.11.007_bib117","doi-asserted-by":"crossref","first-page":"1136","DOI":"10.1038\/leu.2016.308","article-title":"Calreticulin mutant mice develop essential thrombocythemia that is ameliorated by the JAK inhibitor ruxolitinib","volume":"31","author":"Shide","year":"2017","journal-title":"Leukemia"},{"issue":"8","key":"10.1016\/j.jbior.2018.11.007_bib118","doi-asserted-by":"crossref","first-page":"1479","DOI":"10.1084\/jem.20151136","article-title":"Loss of Ezh2 synergizes with JAK2-V617F in initiating myeloproliferative neoplasms and promoting myelofibrosis","volume":"213","author":"Shimizu","year":"2016","journal-title":"J. Exp. Med."},{"issue":"3","key":"10.1016\/j.jbior.2018.11.007_bib119","doi-asserted-by":"crossref","first-page":"382","DOI":"10.1111\/bjh.14061","article-title":"Incidence and patient survival of myeloproliferative neoplasms and myelodysplastic\/myeloproliferative neoplasms in the United States, 2001-12","volume":"174","author":"Srour","year":"2016","journal-title":"Br. J. Haematol."},{"issue":"7","key":"10.1016\/j.jbior.2018.11.007_bib120","doi-asserted-by":"crossref","first-page":"1217","DOI":"10.1038\/leu.2011.77","article-title":"DNMT3A mutations in myeloproliferative neoplasms","volume":"25","author":"Stegelmann","year":"2011","journal-title":"Leukemia"},{"key":"10.1016\/j.jbior.2018.11.007_bib121","doi-asserted-by":"crossref","first-page":"6691","DOI":"10.1038\/ncomms7691","article-title":"Genetic variation at MECOM, TERT, JAK2 and HBS1L-MYB predisposes to myeloproliferative neoplasms","volume":"6","author":"Tapper","year":"2015","journal-title":"Nat. Commun."},{"issue":"5","key":"10.1016\/j.jbior.2018.11.007_bib122","doi-asserted-by":"crossref","first-page":"905","DOI":"10.1038\/leu.2009.47","article-title":"TET2 mutations and their clinical correlates in polycythemia vera, essential thrombocythemia and myelofibrosis","volume":"23","author":"Tefferi","year":"2009","journal-title":"Leukemia"},{"issue":"3","key":"10.1016\/j.jbior.2018.11.007_bib123","doi-asserted-by":"crossref","first-page":"475","DOI":"10.1038\/leu.2011.253","article-title":"IDH mutations in primary myelofibrosis predict leukemic transformation and shortened survival: clinical evidence for leukemogenic collaboration with JAK2V617F","volume":"26","author":"Tefferi","year":"2012","journal-title":"Leukemia"},{"issue":"12","key":"10.1016\/j.jbior.2018.11.007_bib124","doi-asserted-by":"crossref","first-page":"2300","DOI":"10.1038\/leu.2014.148","article-title":"Calreticulin mutations and long-term survival in essential thrombocythemia","volume":"28","author":"Tefferi","year":"2014","journal-title":"Leukemia"},{"issue":"8","key":"10.1016\/j.jbior.2018.11.007_bib125","doi-asserted-by":"crossref","first-page":"E121","DOI":"10.1002\/ajh.23743","article-title":"Type 1 versus Type 2 calreticulin mutations in essential thrombocythemia: a collaborative study of 1027 patients","volume":"89","author":"Tefferi","year":"2014","journal-title":"Am. J. Hematol."},{"issue":"15","key":"10.1016\/j.jbior.2018.11.007_bib126","doi-asserted-by":"crossref","first-page":"2465","DOI":"10.1182\/blood-2014-07-588426","article-title":"The prognostic advantage of calreticulin mutations in myelofibrosis might be confined to type 1 or type 1-like CALR variants","volume":"124","author":"Tefferi","year":"2014","journal-title":"Blood"},{"key":"10.1016\/j.jbior.2018.11.007_bib127","doi-asserted-by":"crossref","first-page":"1494","DOI":"10.1038\/leu.2014.57","article-title":"CALR and ASXL1 mutations-based molecular prognostication in primary myelofibrosis: an international study of 570 patients","volume":"28","author":"Tefferi","year":"2014","journal-title":"Leukemia"},{"issue":"23","key":"10.1016\/j.jbior.2018.11.007_bib128","doi-asserted-by":"crossref","first-page":"354","DOI":"10.1182\/blood.V126.23.354.354","article-title":"Targeted next-generation sequencing in polycythemia vera and essential thrombocythemia","volume":"126","author":"Tefferi","year":"2015","journal-title":"Blood"},{"issue":"2","key":"10.1016\/j.jbior.2018.11.007_bib129","doi-asserted-by":"crossref","first-page":"105","DOI":"10.1182\/bloodadvances.2016000208","article-title":"Targeted deep sequencing in primary myelofibrosis","volume":"1","author":"Tefferi","year":"2016","journal-title":"Blood advances"},{"issue":"1","key":"10.1016\/j.jbior.2018.11.007_bib130","doi-asserted-by":"crossref","first-page":"21","DOI":"10.1182\/bloodadvances.2016000216","article-title":"Targeted deep sequencing in polycythemia vera and essential thrombocythemia","volume":"1","author":"Tefferi","year":"2016","journal-title":"Blood advances"},{"issue":"1","key":"10.1016\/j.jbior.2018.11.007_bib131","doi-asserted-by":"crossref","first-page":"375","DOI":"10.1182\/blood-2006-12-062125","article-title":"Leukemic blasts in transformed <em>JAK2-V617F<\/em>\u2013positive myeloproliferative disorders are frequently negative for the <em>JAK2-V617F<\/em> mutation","volume":"110","author":"Theocharides","year":"2007","journal-title":"Blood"},{"issue":"25","key":"10.1016\/j.jbior.2018.11.007_bib132","doi-asserted-by":"crossref","first-page":"3253","DOI":"10.1182\/blood-2016-02-696310","article-title":"Homozygous <em>calreticulin<\/em> mutations in patients with myelofibrosis lead to acquired myeloperoxidase deficiency","volume":"127","author":"Theocharides","year":"2016","journal-title":"Blood"},{"issue":"8","key":"10.1016\/j.jbior.2018.11.007_bib133","doi-asserted-by":"crossref","first-page":"3931","DOI":"10.1182\/blood-2007-08-107748","article-title":"Ratio of mutant JAK2-V617F to wild-type Jak2 determines the MPD phenotypes in transgenic mice","volume":"111","author":"Tiedt","year":"2008","journal-title":"Blood"},{"issue":"1","key":"10.1016\/j.jbior.2018.11.007_bib134","doi-asserted-by":"crossref","first-page":"100","DOI":"10.1002\/ajh.24946","article-title":"JAK2, and TERT polymorphisms defining the genetic predisposition to myeloproliferative neoplasms: a study on 939 patients","volume":"93","author":"Trifa","year":"2018","journal-title":"Am. J. Hematol."},{"key":"10.1016\/j.jbior.2018.11.007_bib135","series-title":"ASXL1\/EZH2 Mutations Promote Clonal Expansion of Neoplastic HSC and Impair Erythropoiesis in PMF. Leukemia","author":"Triviai","year":"2018"},{"issue":"3","key":"10.1016\/j.jbior.2018.11.007_bib136","doi-asserted-by":"crossref","first-page":"840","DOI":"10.1182\/blood-2006-12-064287","article-title":"Clinical profile of homozygous JAK2 617V>F mutation in patients with polycythemia vera or essential thrombocythemia","volume":"110","author":"Vannucchi","year":"2007","journal-title":"Blood"},{"issue":"3","key":"10.1016\/j.jbior.2018.11.007_bib137","doi-asserted-by":"crossref","first-page":"330","DOI":"10.1002\/ajh.24973","article-title":"Impact of gene mutations on treatment response and prognosis of acute myeloid leukemia secondary to myeloproliferative neoplasms","volume":"93","author":"Venton","year":"2018","journal-title":"Am. J. Hematol."},{"issue":"24","key":"10.1016\/j.jbior.2018.11.007_bib138","doi-asserted-by":"crossref","first-page":"2585","DOI":"10.1182\/blood-2015-07-659060","article-title":"Clinical and molecular response to interferon-alpha therapy in essential thrombocythemia patients with CALR mutations","volume":"126","author":"Verger","year":"2015","journal-title":"Blood"},{"issue":"10","key":"10.1016\/j.jbior.2018.11.007_bib139","doi-asserted-by":"crossref","first-page":"94","DOI":"10.1038\/s41408-018-0133-0","article-title":"Ropeginterferon alpha-2b targets JAK2V617F-positive polycythemia vera cells in vitro and in vivo","volume":"8","author":"Verger","year":"2018","journal-title":"Blood Canc. J."},{"issue":"7","key":"10.1016\/j.jbior.2018.11.007_bib140","doi-asserted-by":"crossref","first-page":"821","DOI":"10.3324\/haematol.2016.143644","article-title":"Ruxolitinib versus best available therapy in patients with polycythemia vera: 80-week follow-up from the RESPONSE trial","volume":"101","author":"Verstovsek","year":"2016","journal-title":"Haematologica"},{"issue":"24","key":"10.1016\/j.jbior.2018.11.007_bib141","doi-asserted-by":"crossref","first-page":"6468","DOI":"10.1182\/blood-2011-08-372813","article-title":"Homologous recombination of wild-type JAK2, a novel early step in the development of myeloproliferative neoplasm","volume":"118","author":"Vilaine","year":"2011","journal-title":"Blood"},{"issue":"15","key":"10.1016\/j.jbior.2018.11.007_bib142","doi-asserted-by":"crossref","first-page":"3550","DOI":"10.1182\/blood-2011-12-397554","article-title":"Essential role for Stat5a\/b in myeloproliferative neoplasms induced by BCR-ABL1 and JAK2(V617F) in mice","volume":"119","author":"Walz","year":"2012","journal-title":"Blood"},{"issue":"4","key":"10.1016\/j.jbior.2018.11.007_bib143","doi-asserted-by":"crossref","first-page":"938","DOI":"10.1038\/leu.2014.20","article-title":"The relationship of JAK2(V617F) and acquired UPD at chromosome 9p in polycythemia vera","volume":"28","author":"Wang","year":"2014","journal-title":"Leukemia"},{"issue":"19","key":"10.1016\/j.jbior.2018.11.007_bib144","doi-asserted-by":"crossref","first-page":"2987","DOI":"10.1182\/blood-2014-02-558015","article-title":"JAK2 inhibitors do not affect stem cells present in the spleens of patients with myelofibrosis","volume":"124","author":"Wang","year":"2014","journal-title":"Blood"},{"issue":"8","key":"10.1016\/j.jbior.2018.11.007_bib145","doi-asserted-by":"crossref","first-page":"644","DOI":"10.1016\/j.exphem.2015.11.005","article-title":"Acquired uniparental disomy of chromosome 9p in hematological malignancies","volume":"44","author":"Wang","year":"2016","journal-title":"Exp. Hematol."},{"issue":"15","key":"10.1016\/j.jbior.2018.11.007_bib146","doi-asserted-by":"crossref","first-page":"3539","DOI":"10.1182\/blood-2011-03-345215","article-title":"Critical requirement for Stat5 in a mouse model of polycythemia vera","volume":"119","author":"Yan","year":"2012","journal-title":"Blood"},{"issue":"26","key":"10.1016\/j.jbior.2018.11.007_bib147","doi-asserted-by":"crossref","first-page":"3410","DOI":"10.1182\/blood-2015-11-679431","article-title":"Loss of Ezh2 cooperates with Jak2V617F in the development of myelofibrosis in a mouse model of myeloproliferative neoplasm","volume":"127","author":"Yang","year":"2016","journal-title":"Blood"},{"issue":"10","key":"10.1016\/j.jbior.2018.11.007_bib148","doi-asserted-by":"crossref","first-page":"2122","DOI":"10.1038\/leu.2017.1","article-title":"Activating JAK2 mutants reveal cytokine receptor coupling differences that impact outcomes in myeloproliferative neoplasm","volume":"31","author":"Yao","year":"2017","journal-title":"Leukemia"},{"key":"10.1016\/j.jbior.2018.11.007_bib149","doi-asserted-by":"crossref","first-page":"462","DOI":"10.1038\/leu.2017.233","article-title":"The JAK2V617F-bearing vascular niche promotes clonal expansion in myeloproliferative neoplasms","volume":"32","author":"Zhan","year":"2017","journal-title":"Leukemia"},{"issue":"19","key":"10.1016\/j.jbior.2018.11.007_bib150","doi-asserted-by":"crossref","first-page":"4480","DOI":"10.1182\/blood-2011-11-390252","article-title":"Genetic analysis of patients with leukemic transformation of myeloproliferative neoplasms shows recurrent <em>SRSF2<\/em> mutations that are associated with adverse outcome","volume":"119","author":"Zhang","year":"2012","journal-title":"Blood"}],"container-title":["Advances in Biological Regulation"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S221249261830157X?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S221249261830157X?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,5,15]],"date-time":"2026-05-15T12:56:34Z","timestamp":1778849794000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S221249261830157X"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,1]]},"references-count":150,"alternative-id":["S221249261830157X"],"URL":"https:\/\/doi.org\/10.1016\/j.jbior.2018.11.007","relation":{},"ISSN":["2212-4926"],"issn-type":[{"value":"2212-4926","type":"print"}],"subject":[],"published":{"date-parts":[[2019,1]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Heterogeneity in myeloproliferative neoplasms: Causes and consequences","name":"articletitle","label":"Article Title"},{"value":"Advances in Biological Regulation","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jbior.2018.11.007","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2018 Elsevier Ltd. All rights reserved.","name":"copyright","label":"Copyright"}]}}